背景:软组织的浪费导致老化的中脸皮肤变平和收缩。多核苷酸高度纯化技术(PN-HPT®)证明了皮肤的水合作用和弹性以及成纤维细胞的活力和活性。
目的:为了探索PN-HPT®在开放式设计中的中三分之一复兴中的价值,40名现实生活中接受动态治疗的女性的探索性前瞻性队列研究。
方法:在基线时进行三次治疗(2毫升预装注射器,含10毫克/毫升PN-HPT®,10mg/ml透明质酸,200mM甘露醇)作为皮内凝胶,3周后(含20mg/mlPN-HPT®皮内凝胶的2-ml预填充注射器)和6周后(与基线相同的治疗)。该方案允许在眼周和眼睑区域需要时用专门配制的PN-HPT®(7.5mg/ml)进行补充治疗。
方法:基线时面部中间三分之一的顺序照片,第三次治疗和第三次治疗后6-8周;总体皮肤质量和质地评分,皮肤质量决定因素(皱纹和皮肤粗糙度,皮肤弹性,皮肤亮度),疤痕外观,和主观满意度即兴10厘米视觉模拟量表。
结果:总体皮肤质量和质地显着改善(从基线阶段的7.0±1.06到随访阶段的7.8±0.99),与皱纹和皮肤粗糙度的高度显着改善相关,弹性,和亮度(-17.1%,+39.6%,和+51.1%,分别)。痤疮后疤痕的严重程度评分从7.6±1.32降至4.2±2.13。治疗结束时个体满意度评分:0.8±0.28。
结论:PN-HPT®候选作为面部中期第三次年轻化的有价值的选择。进一步的试验有望证实这些早期结果。
BACKGROUND: Wasting of soft tissues leads to flattening and deflation of the aging midface skin. Polynucleotides Highly Purified Technology (PN-HPT® ) demonstrated dermal hydration and elasticity as well as fibroblasts vitality and activity.
OBJECTIVE: To probe the value of PN-HPT® in middle third rejuvenation in an open-design, exploratory prospective cohort study in 40 real-life ambulatorily treated women.
METHODS: Three treatment sessions-at baseline (2-ml prefilled syringe containing 10 mg/ml PN-HPT® , 10 mg/ml hyaluronic acid, 200 mM mannitol) as intradermic gel, and after 3 weeks (2-ml prefilled syringe containing 20 mg/ml PN-HPT® intradermic gel) and 6 weeks (same treatment as baseline). The protocol allowed supplemental treatment with specifically formulated PN-HPT® (7.5 mg/ml) when needed in periocular and eyelid areas.
METHODS: sequential photographs of the facial middle third at baseline, third treatment session and 6-8 weeks after the third treatment session; scoring of overall skin quality and texture, skin quality determinants (wrinkles and skin roughness, skin elasticity, skin brightness), scar appearance, and subjective satisfaction with impromptu 10-cm Visual Analogue Scales.
RESULTS: Significant improvement of overall skin quality and texture (from 7.0 ± 1.06 at baseline session to 7.8 ± 0.99 at follow-up), associated with highly significant improvements of wrinkles and skin roughness, elasticity, and brightness (-17.1%, +39.6%, and +51.1%, respectively). The severity scores of post-acne scars decreased from 7.6 ± 1.32 to 4.2 ± 2.13. Individual satisfaction score at the end of treatment: 0.8 ± 0.28.
CONCLUSIONS: PN-HPT® candidate as a valuable option for facial middle third rejuvenation. Further trials will hopefully confirm these early results.